下一代肿瘤不可知靶点即将出现
Next-generation tumor-agnostic targets on the horizon.
肿瘤不可知药物开发将肿瘤学重新聚焦于共享的分子依赖性而非组织来源，从而能够针对跨肿瘤的罕见可操作驱动因素进行高效开发。
99.3分
★★★★★
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
骨肉瘤免疫微环境及免疫治疗机制的新见解
英文原题：New insights into the mechanisms of the immune microenvironment and immunotherapy in osteosarcoma.
研究概要
尽管手术和化疗提高了局限性病例的生存率，但肺转移使生存率显著降低至约20%，凸显了对新型治疗的需求。
中文摘要
骨肉瘤是一种主要影响青少年的恶性骨肿瘤，具有高度侵袭性和较差的预后。虽然手术和化疗提高了局限性病例的生存率，但肺转移使生存率显著降低至约20%，凸显了对新型治疗的需求。免疫治疗利用免疫系统靶向骨肉瘤细胞，显示出前景。本综述总结了骨肉瘤的生物学特征、肺转移机制以及肿瘤免疫微环境（TME）。内容涉及近期的免疫治疗进展，包括单克隆抗体、肿瘤疫苗、免疫细胞疗法、检查点抑制剂和溶瘤病毒，并讨论了这些疗法与标准治疗的联合应用。
展开英文摘要原文
Osteosarcoma, a malignant bone tumor primarily affecting adolescents, is highly invasive with a poor prognosis. While surgery and chemotherapy have improved survival for localized cases, pulmonary metastasis significantly reduces survival to approximately 20%, highlighting the need for novel treatments. Immunotherapy, which leverages the immune system to target osteosarcoma cells, shows promise. This review summarizes the biological characteristics of osteosarcoma, mechanisms of pulmonary metastasis, and the tumor immune microenvironment (TME). It involves recent immunotherapy advances, including monoclonal antibodies, tumor vaccines, immune cell therapies, checkpoint inhibitors, and oncolytic viruses, and discusses combining these with standard treatments.
论文信息
- 作者
- Luo C、Min X、Zhang D
- 第一作者单位
- Department of Orthopedic Trauma, Zhuji People's Hospital of Zhejiang Province, Zhuji, Zhejiang, China.China
- 通讯作者单位
- Department of Emergency and Critical Care, Shanghai Changzheng Hospital, Shanghai, China.China
- 文献类型
- 综述
- 期刊
- Frontiers in immunology2024
- 原文标识
- PubMed 39896817 · DOI 10.3389/fimmu.2024.1539696